• ISRIB and Inflammation-Associated Memory Loss

  2026-10-05

  A source-grounded overview of how ISRIB was studied in a mouse model of inflammation-associated accelerated forgetting, what the findings suggest about ISR signaling and memory retention, and why the evidence does not yet establish clinical efficacy or direct PERK inhibition.

• Etomoxir in Immunometabolism Research

  2026-10-04

  Etomoxir is widely used as a pharmacological probe of mitochondrial fatty acid oxidation, but its interpretation requires caution because supplier-described activity also includes diacylglycerol acyltransferase inhibition and because the supplied human whole-blood study is a protocol rather than an Etomoxir-specific efficacy trial. This overview compares the available evidence, outlines conceptual applications in immunometabolism and neuroinflammation research, and defines key limitations across cell, whole-blood, and animal models.

• EZ Cap™ Cas9 mRNA: From Editing to Pharming

  2026-10-03

  EZ Cap™ Cas9 mRNA (m1Ψ) connects transient Cas9 expression with a broader evidence framework for CRISPR-Cas9 genome editing and animal pharming. This article interprets Cap1, m1Ψ, and the rabbit study without overstating what product chemistry alone can prove.

• Dual Luciferase Reporter Gene System: Practical Guide

  2026-10-02

  The Dual Luciferase Reporter Gene System pairs firefly signal strength with Renilla normalization to make promoter and transcription-factor experiments more quantitative. This guide connects the K1136 workflow with the MYC2–LBD40/42–CRL3BPM4 model of tomato defense while clearly separating validated mammalian-cell applications from future cross-domain experiments.

• HBV G1896A Drives HCC Through ER Stress and Glycolysis

  2026-10-01

  This MedComm study identifies a mechanistic link between the HBV precore G1896A mutation, PERK–ATF4 endoplasmic reticulum stress signaling, and PFKFB3-dependent aerobic glycolysis in hepatocellular carcinoma. Its rescue and in vivo experiments suggest that the ATF4–PFKFB3 axis contributes to mutation-associated tumor growth, invasion, and metastasis, while also providing a framework for studying HBV-related metabolic reprogramming.

• In Situ CAR-M Reprogramming for HCC Immunotherapy

  2026-10-01

  The reference study develops a GPC3-targeted CAR macrophage design that combines self-secreted IFN-γ with a dominant-negative SIRPα extracellular domain. Delivered as lipid nanoparticle-encapsulated mRNA, the construct reprogrammed endogenous macrophages, strengthened inflammatory activity, disrupted CD47–SIRPα signaling, and improved antitumor responses in hepatocellular carcinoma models.

• Cl-Amidine: PAD4 Inhibition for Research

  2026-09-30

  Cl-Amidine trifluoroacetate salt is an in vitro PAD4 inhibitor used to study histone citrullination, immune signaling, and disease models. The product listing reports a PAD4 IC50 of 5.9 μM, while its murine septic shock evidence should not be interpreted as clinical efficacy.

• α-Bungarotoxin for Nicotinic Receptor Blockade

  2026-09-30

  Use α-Bungarotoxin as a practical α7 nAChR perturbation tool in neuronal, neuromuscular, and placental assays. This guide connects receptor blockade to causal pathway testing, with executable setup conditions and troubleshooting for cholinergic experiments.

• Rotigotine Analytical Methods: Findings and Implications

  2026-09-29

  This review consolidates HPLC, chiral, and stability-indicating approaches for rotigotine raw materials and transdermal formulations, with particular attention to synthesis-related impurities and oxidative degradation. Its main practical contribution is a unified quality-control framework that supports formulation development while highlighting unresolved needs for impurity characterization in pharmacokinetic and toxicological studies.

• Proteinase K for Fungal EV DNA Workflows

  2026-09-29

  Proteinase K is more than a routine digestion reagent in fungal extracellular-vesicle research. This guide explains how its biochemical operating window, contaminant-removal capacity, and DNA-preserving behavior can improve assay interpretation in Candida albicans workflows while clarifying important experimental limits.

• Proteinase K Workflows for High-Integrity DNA

  2026-09-28

  Build robust DNA extraction workflows around Proteinase K for broad protein digestion, nuclease decontamination, and preservation of genomic DNA. The same enzyme can also serve as a practical counter-screening control when interpreting selective protease-inhibitor assays.

• Nav1.5 Ser571 Phosphorylation in Cardiac Aging

  2026-09-28

  A 2024 mouse study links Nav1.5 Ser571 phosphorylation and increased late sodium current to delayed ventricular repolarization and impaired diastolic function during aging. By comparing gain- and loss-of-function channel models with wild-type animals, the researchers provide evidence that late-current regulation can shape the timing and severity of age-associated cardiac dysfunction.

• Rotigotine hydrochloride in PD model workflows

  2026-09-27

  Use Rotigotine hydrochloride to probe dopamine-receptor signaling across neuroprotection assays and Parkinson’s disease models, including autonomic bladder outcomes. A route-dependent rat study shows why dose, administration route, and measurement timing must be designed together—not transferred directly from one workflow to another.

• Etomoxir Workflows for Immunometabolic Research

  2026-09-26

  Use Etomoxir to test how mitochondrial fatty acid entry shapes stimulated immune-cell responses, with a workflow that pairs whole-blood cytokine measurements with dose and viability controls. The guide separates CPT-1-focused experiments from higher-concentration effects and shows how to extend findings cautiously into cell and neuroinflammation models.

• GS967 and the Aging Heart: Translational Strategy

  2026-09-25

  A mechanistic and practical guide to using GS967 to investigate late sodium current, age-linked cardiac dysfunction, and arrhythmia phenotypes. Learn how pharmacological inhibition can complement genetic models and in vitro cardiac electrophysiology while keeping translational conclusions appropriately bounded.

8088 records 4/540 page Previous Next 12345 下5页 Last page